CHICAGO, Nov. 8, 2018 /PRNewswire/ -- Active people who are struggling with knee pain or knee cartilage abnormalities may benefit from a Rush University Medical Center clinical trial using an innovative new procedure for cartilage regrowth.
Drs. Adam B. Yanke and Brian Cole, orthopedic surgeons and sports medicine physicians at Midwest Orthopaedics at Rush (MOR) are some of the only physicians nationwide conducting clinical trials for GelrinC.
Using a microfracture procedure, the surgeon creates tiny holes in the bone's surface so bone marrow cells can repopulate where cartilage has been damaged or deteriorated. GelrinC material is injected in liquid form over the microfracture and UV light turns it into a gel that keeps it in place, which encourages the regeneration of cartilage.
To enroll in the study, patients must be:
About GelrinC
GelrinC is a biodegradable implant used in conjunction with the standard technique of microfracture. The dense gel barrier promotes the regeneration of cartilage and its application ensures that no healthy tissue needs to be removed in the procedure, preserving bone stock. European clinical studies on this procedure have shown promising results. For more information on GelrinC: gelrinc.com.
About Midwest Orthopaedics at Rush
Midwest Orthopaedics at Rush (MOR) doctors are team physicians for the Chicago Bulls, Chicago White Sox, Chicago Fire Soccer Club and Joffrey Ballet, among others. US News & World Report ranks the orthopedic program at Rush University Medical Center – staffed by MOR physicians -- as No. 4 in the nation. MOR has offices at Rush University Medical Center in Chicago; Oak Park; Westchester; Winfield; Munster, Indiana; and coming soon to Oak Brook and Naperville. For more information or to make an appointment, visit rushortho.com
Advertisement
Drs. Adam B. Yanke and Brian Cole, orthopedic surgeons and sports medicine physicians at Midwest Orthopaedics at Rush (MOR) are some of the only physicians nationwide conducting clinical trials for GelrinC.
Advertisement
Using a microfracture procedure, the surgeon creates tiny holes in the bone's surface so bone marrow cells can repopulate where cartilage has been damaged or deteriorated. GelrinC material is injected in liquid form over the microfracture and UV light turns it into a gel that keeps it in place, which encourages the regeneration of cartilage.
To enroll in the study, patients must be:
- Between the ages of 18 and 50;
- Suffering from knee pain but are not yet candidates for knee replacement;
- OR already diagnosed with a cartilage abnormality and not yet a candidate for knee replacement;
- Willing to undergo initial evaluation and imaging to determine if pain is caused by cartilage abnormalities;
- Motivated to participate in the GelrinC microfracture study.
About GelrinC
GelrinC is a biodegradable implant used in conjunction with the standard technique of microfracture. The dense gel barrier promotes the regeneration of cartilage and its application ensures that no healthy tissue needs to be removed in the procedure, preserving bone stock. European clinical studies on this procedure have shown promising results. For more information on GelrinC: gelrinc.com.
About Midwest Orthopaedics at Rush
Midwest Orthopaedics at Rush (MOR) doctors are team physicians for the Chicago Bulls, Chicago White Sox, Chicago Fire Soccer Club and Joffrey Ballet, among others. US News & World Report ranks the orthopedic program at Rush University Medical Center – staffed by MOR physicians -- as No. 4 in the nation. MOR has offices at Rush University Medical Center in Chicago; Oak Park; Westchester; Winfield; Munster, Indiana; and coming soon to Oak Brook and Naperville. For more information or to make an appointment, visit rushortho.com
View original content:http://www.prnewswire.com/news-releases/patients-with-knee-cartilage-defects-recruited-for-chicago-study-using-cutting-edge-procedure-to-help-regrow-cartilage-300746795.html
SOURCE Midwest Orthopaedics at Rush
